Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1979 Feb;42(2):143–150. doi: 10.1136/jnnp.42.2.143

Long-term treatment of Parkinson's disease with bromocriptine.

A Rascol, B Guiraud, J L Montastruc, J David, M Clanet
PMCID: PMC490179  PMID: 422961

Abstract

BRomocriptine (15-75 mg per day) alone or with L-dopa was studied during five to 29 months on 44 patients with Parkinson's disease. Used as sole therapeutic agent, it was found excellent in 12 patients who had never received regular L-dopa treatment either because it was never attempted or because of intolerance from the outset. Its anti-Parkinsonism activity was comparable with L-dopa. The gain was stable in the long term until this report. The side effects of L-dopa were not seen after bromocriptine. In cases where L-dopa had ceased to be active, bromocriptine produced a further improvement if mental deterioration was not associated. In very advanced forms of Parkinson's disease with associated dementia, bromocriptine did not produce durable results. Bromocriptine did not improve the "on-off" effects but reduced a number of the side effects of L-dopa, in particular cardiac, painful contractions, and dyskinesia without "on-off" effects.

Full text

PDF
143

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Calne D. B., Teychenne P. F., Claveria L. E., Eastman R., Greenacre J. K., Petrie A. Bromocriptine in Parkinsonism. Br Med J. 1974 Nov 23;4(5942):442–444. doi: 10.1136/bmj.4.5942.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Calne D. B., Teychenne P. F., Leigh P. N., Bamji A. N., Greenacre J. K. Treatment of parkinsonism with bromocriptine. Lancet. 1974 Dec 7;2(7893):1355–1356. doi: 10.1016/s0140-6736(74)92219-3. [DOI] [PubMed] [Google Scholar]
  3. Castaigne P., Laplane D., Bousser M. G., Bories F. Traitement de la maladie de Parkinson par la bromocriptine. Nouv Presse Med. 1976 Apr 23;6(17):1482–1482. [PubMed] [Google Scholar]
  4. Corrodi H., Farnebo L. O., Fuxe K., Hamberger B. Effect of ergot drugs on central 5-hydroxytryptamine neurons: evidence for 5-hydroxytryptamine release or 5-hydroxytryptamine receptor stimulation. Eur J Pharmacol. 1975 Feb;30(2):172–181. doi: 10.1016/0014-2999(75)90097-7. [DOI] [PubMed] [Google Scholar]
  5. Corrodi H., Fuxe K., Hökfelt T., Lidbrink P., Ungerstedt U. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol. 1973 May;25(5):409–412. doi: 10.1111/j.2042-7158.1973.tb10037.x. [DOI] [PubMed] [Google Scholar]
  6. Frattola L., Albizzati M. G., Spano P. F., Trabucchi M. Effet de la bromocryptine sur les fluctuations thérapeutiques secondaires à la dopathérapie. Phénomène "one-off" chez les parkinsoniens. 1976 Aug 28-Sep 4Nouv Presse Med. 5(28):1761–1761. [PubMed] [Google Scholar]
  7. Gautier J. C., Durand J. P. Traitement des syndromes parkinsoniens par la bromocriptine. Nouv Presse Med. 1977 Jan 22;6(3):171–174. [PubMed] [Google Scholar]
  8. Gron U. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease. Acta Neurol Scand. 1977 Sep;56(3):269–273. [PubMed] [Google Scholar]
  9. Hofmann W. W., Angel R. W. Transient responses of the normal and diseased motor system to sudden load changes. Neurology. 1967 Oct;17(10):952–960. doi: 10.1212/wnl.17.10.952. [DOI] [PubMed] [Google Scholar]
  10. Kartzinel R., TEYCHENNE P., Gillespie M. M., Perlow M., Gielen A. C., Sadowsky D. A., Calne D. B. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet. 1976 Aug 7;2(7980):272–275. doi: 10.1016/s0140-6736(76)90728-5. [DOI] [PubMed] [Google Scholar]
  11. Kissel P., Andre J. M., Jacquier A. Efficacité de la bromocriptine chez deux parkinsoniens lévodopa-résistants. Nouv Presse Med. 1976 Jan 24;5(4):210–210. [PubMed] [Google Scholar]
  12. Kristensen O., Hansen E. Bromocriptine in the treatment of advanced Parkinsonism. Acta Neurol Scand. 1977 Sep;56(3):274–276. doi: 10.1111/j.1600-0404.1977.tb01434.x. [DOI] [PubMed] [Google Scholar]
  13. Lees A. J., Shaw K. M., Stern G. M. Letter: Bromocriptine in parkinsonism. Lancet. 1975 Oct 11;2(7937):709–710. doi: 10.1016/s0140-6736(75)90809-0. [DOI] [PubMed] [Google Scholar]
  14. Lhermitte F., Agid Y., Feuerstein C., Serre F., Signoret J. L., Studler J. M., Bonnet A. M. Mouvements anormaux provoqués par la L-DOPA dans la maladie de Parkinson: corrélation avec les concentrations plasmatiques de DOPA et de O-méthyl-DOPA. Rev Neurol (Paris) 1977 Aug-Sep;133(8-9):445–454. [PubMed] [Google Scholar]
  15. Lieberman A., Kupersmith M., Estey E., Goldstein M. Treatment of parkinson's disease with bromocriptine. N Engl J Med. 1976 Dec 16;295(25):1400–1404. doi: 10.1056/NEJM197612162952504. [DOI] [PubMed] [Google Scholar]
  16. Marsden C. D., Parkes J. D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1977 Feb 12;1(8007):345–349. doi: 10.1016/s0140-6736(77)91146-1. [DOI] [PubMed] [Google Scholar]
  17. Meco G., Casacchia M., Zamponi A., Agnoli A. Le CB 154 dans le traitement de la maladie de Parkinson. Résultats d'une association avec la L-DOPA + IDD. Schweiz Rundsch Med Prax. 1976 May 4;65(18):557–559. [PubMed] [Google Scholar]
  18. Parkes J. D., Marsden C. D., Donaldson I., Galea-Debono A., Walters J., Kennedy G., Asselman P. Bromocriptine treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1976 Feb;39(2):184–193. doi: 10.1136/jnnp.39.2.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Petit H., Destee A. Bromocriptine et maladie de Parkinson: premiers résultats. Lille Med. 1977 Jun-Jul;22(6):362–365. [PubMed] [Google Scholar]
  20. Pycock C. J., Marsden C. D. Central deopaminergic receptor supersensitivity and its relevance to Parkinson's disease. J Neurol Sci. 1977 Jan-Feb;31(1):113–121. doi: 10.1016/0022-510x(77)90009-0. [DOI] [PubMed] [Google Scholar]
  21. Simon P., Goujet M. A., Chermat R., Boissier J. R. Etude pharmacologique d'un métabolite présumé de la dopamine, la tétrahydropapavéroline. Therapie. 1971 Nov-Dec;26(6):1175–1192. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES